News Focus
News Focus
icon url

dewophile

06/20/23 10:58 AM

#247605 RE: DewDiligence #247604

There are some companies that rely heavily on a small number of products for revenue where there are fewer moving parts. Regeneron is a prime example. Maybe it’s because eyelea is a part B drug amd that doesn’t go into effect until 2026??